Listen to this article on the DDW Podcast: Immutep is working to understand and develop therapeutics that relate to Lymphocyte Activation gene-3 or ‘LAG-3’ which is a cell surface molecule that plays a vital role in regulating the immune system. LAG-3 was discovered by Frederic Triebel, CSO, Immutep, putting the company… Read More
On 4 and 5 July 2022, The British Pharmacological Society and ELRIG UK will explore new pharmacological modalities of differing mechanisms, shapes and sizes and how these are being translated to create patient benefit at the Francis Crick Institute in London, UK. This is both a free and in-person event. Read More
For the last seven years, the LSX World Congress has bought together biotech, medtech and healthtech executives to connect with the capital, intelligence, innovation, and partners they need to grow their businesses. Back in-person for 2022, the 8th Congress takes place 10-11 May at 133 Houndsditch in London. … Read More
PerkinElmer has expanded its in vivo imaging portfolio with the launch of the Vega imaging system, an ultrasound platform that combines hands-free, automated technology with high-throughput capability to accelerate non-invasive research and drug development studies of cancer, liver and kidney disease, cardiology and more. The Vega system … Read More
Neuro-Bio, a biotechnology company developing a first-in-class treatment for neurodegenerative disease, has found its new drug candidate effectively treats the signs of neurodegeneration in a mouse model of Alzheimer’s disease. Publishing their work in Alzheimer’s & Dementia: Translational Research & Clinical Interventions (TRCI)… Read More
Lonza has expanded its human stem cell offerings to provide human cord blood CD34+ haematopoietic stem cells (CB-CD34+ HSCs) in large batch sizes, meeting a rapidly expanding market need. CB-CD34+ HSCs are the preferred cell choice for creating humanised mouse models, which are critical for preclinical… Read More
C2i Genomics, a cancer intelligence company, has launched its C2inform minimal residual disease (MRD) test across Europe after obtaining CE-IVD marking in the EU, UK and Switzerland. The company also announced the completion of several clinical trials across the globe, including cancer centers in Europe, US and… Read More
PerkinElmer has announced two ready-to-use HTRF and AlphaLISA no-wash assay kits designed to quickly and easily detect and quantify CHO HCP impurities during biopharmaceutical manufacturing. Recombinant therapeutic proteins, such as monoclonal antibodies, some vaccines and other biologics, must be free of residual host cell protein (HCP) impurities… Read More
When he was 17 years old, Joe Landolina created a revolutionary gel. Now, he is 29 years old and co-founder and CEO of Cresilon, his homegrown Brooklyn-based biotech company that recently submitted the gel for FDA 510(k) clearance for human use and raised $38.5 million in Series A3 financing last… Read More